Key Trends Shaping the Future Stelara (Ustekinumab) Market From 2025-2034: Innovation In The Stelara Biosimilar Market

What Is the Estimated Market Size and Growth Rate for the Stelara (Ustekinumab) Market?
In the past few years, there has been a notable expansion in the market size of stelara (ustekinumab). The market, which was valued at $11,177.34 million in 2024, is projected to grow to $11,850.79 million in 2025, representing a compound annual growth rate (CAGR) of 6.0%. The escalating growth during the historical period is associated with factors such as increased healthcare expenditure, the proliferation of specialty drug distribution channels, wider clinical trial programs, investment in research and development, and the growing utilisation of telemedicine for easier access to treatment.

In the upcoming years, the market size of stelara (ustekinumab) is forecasted to experience robust growth. It is projected to reach a valuation of $14,768.48 million in 2029, growing at a compound annual growth rate (CAGR) of 5.7%. Factors contributing to the growth during the forecast period include the expanding uses of stelara, the rising incidence of autoimmune diseases, its high effectiveness in stubborn cases compared to other options, increasing awareness among patients and healthcare professionals, and a heightened emphasis on personalized medicine. The major trends within this period are the embrace of biologic therapies, advancements in drug delivery systems, the use of data in healthcare systems, collaborative efforts and licensing deals among pharmaceutical firms, and progress in biologics production techniques.

What Are the Forces Behind the Rapid Growth of the Stelara (Ustekinumab) Market?
The increasing number of patients affected by psoriasis is anticipated to spur the expansion of the stelara (ustekinumab) market in the future. These patients are affected by a chronic, autoimmune condition that speeds up the lifecycle of skin cells leading to the development of red, scaly patches on the skin. Several elements contribute to the rise in the number of psoriasis patients, like enhanced diagnostics, environmental factors, genetic predisposition, and an aging demographic. Stelara (ustekinumab) specifically works by suppressing interleukin-12 and interleukin-23, thus assisting psoriasis patients by significantly reducing inflammation and the formation of plaques. This results in better skin clarity and prolonged symptom control, which greatly improves the patient's quality of life. In May 2024, as per a paper released by the National Library of Medicine, a medical library based in the US, it was found that in 2022, the rate of psoriasis cases increased to 0.221%, noting 6,930 PsA cases in a population of 3,133,500. As such, the escalating prevalence of psoriasis patients is expected to bolster the expansion of the stelara (ustekinumab) market.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19935&type=smp

Who Are the Dominant Companies Influencing Stelara (Ustekinumab) Market Trends?
Major companies operating in the stelara (ustekinumab) market include Johnson & Johnson

How Is the Stelara (Ustekinumab) Market Evolving?
Innovation in product development, such as the creation of biosimilars to Stelara, is a major trend in the Stelara (ustekinumab) market. These developments aim to provide affordable treatment alternatives for patients suffering from persistent inflammatory ailments. Biosimilars of Stelara are nearly identical drugs designed to replicate the medicinal effects of the original Stelara (Ustekinumab), specifically designed to tackle IL-12 and IL-23, thereby managing autoimmune diseases like psoriasis and psoriatic arthritis. As an example, Accord BioPharma Inc., a biopharmaceutical company based in the US, declared in October 2024 that IMULDOSA (ustekinumab-srlf), a biosimilar to Johnson & Johnson's STELARA (ustekinumab), received the green light from the U.S. Food and Drug Administration (FDA). Notably, IMULDOSA is broad in its indications, offering treatment options for adults with conditions ranging from moderate to severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn's disease, and ulcerative colitis. It is also uniquely approved for use in pediatric patients aged 6 years and above, for conditions like moderate to severe plaque psoriasis and active psoriatic arthritis, demonstrating its versatile applicability across various age categories. The extensive treatment spectrum provided by IMULDOSA makes it a substantial option for handling a variety of immune-mediated inflammatory diseases.

What Are the Different Segmentations in the Stelara (Ustekinumab) Market?
The stelara (ustekinumab)market covered in this report is segmented -

1) By Indication: Plaque Psoriasis; Psoriatic Arthritis; Crohn's Disease; Ulcerative Colitis; Other Indications
2) By Route Of Administration: Subcutaneous Injection; Intravenous Infusion
3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
4) By End User: Pediatric; Adult; Geriatric

Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/stelara-ustekinumab-global-market-report-

Which Region Is at the Forefront of the Stelara (Ustekinumab) Market?
North America was the largest region in the stelara (ustekinumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the stelara (ustekinumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Is Covered In The Stelara (Ustekinumab) Global Market Report?

- Market Size Analysis: Analyze the stelara (ustekinumab) Market Size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the stelara (ustekinumab) market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the Market.
- Market Contribution: Evaluate contributions of different segments to the overall stelara (ustekinumab) market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the stelara (ustekinumab) market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19935

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.